No Efficacy Loss After Multiple Ustekinumab Biosimilar Switches in Psoriasis

Switching to Biosimilar Etanercept Shows No Impact on Efficacy, Safety Across 18 Trials

March 16th 2026

By Skylar Jeremias

Real-world evidence shows switching between etanercept products and etanercept biosimilars preserves efficacy and safety, easing concerns and highlighting nocebo challenges.

Gaps in Knowledge Persist Around Biosimilar Insulin Switching, Review Finds

March 12th 2026

By Skylar Jeremias

Scoping review shows clinicians and patients still worry about biosimilar insulin switching, devices and safety—evidence gaps shape insulin product swaps.

Global Biosimilar Market Sees Structural Shifts, Regulatory Hurdles, and Pipeline Gains

March 10th 2026

By Skylar Jeremias

Global biosimilar market shifts: Celltrion leads biosimilars in Asia, biosimilars in Europe expand, while Sandoz restructures and FDA hurdles loom.

FDA Issues Draft Guidance Aimed at Cutting Expenses for Biosimilar PK Studies

March 9th 2026

By Skylar Jeremias

Biologics eat 51% of drug spending despite being 5% of prescriptions, but the FDA's new draft guidance hopes more competition can close that gap.

Clinician Confidence in Ophthalmology Biosimilars Remains Low Across Europe

March 6th 2026

By Skylar Jeremias

A new analysis dives into why Europe’s eye clinics lag on biosimilars and how education, guidance, and smarter tenders could unlock €747 million in savings.

Biosimilars Development Roundup: Expanding Global Options Amidst Rising US Legal Hurdles

March 5th 2026

By Skylar Jeremias

CHMP backs a fifth teriparatide biosimilar as biosimilars in Europe grow, while US patent fights threaten new biologic competition.

Biosimilar-Backed Triplet Regimen Shows Feasibility in Heavily Pretreated Liver Cancer

February 27th 2026

By Skylar Jeremias

A phase 2 trial showed that combining targeted radiotherapy with PD-1 blockade and a bevacizumab biosimilar can elicit responses in advanced liver cancer.

Omalizumab Biosimilar Entry Linked to Expanded Patient Access, Reduced Spending

February 26th 2026

By Skylar Jeremias

Budget impact analysis finds omalizumab biosimilars in Europe could cut payer costs by €641M in 5 years, expanding access and driving major omalizumab savings.

Postmenopausal Osteoporosis: Clinical Burden, Treatment Barriers, and the Evolving Role of Denosumab Biosimilars

February 25th 2026

Cardinal Health Biosimilar Report: $56 Billion in Savings and the Road to Market Sustainability

February 24th 2026

By Skylar Jeremias

Biosimilars save billions, but FDA’s new guidance, physician concerns, and Humira switchbacks reveal hurdles to a sustainable US market.